Nectar Lifesciences Limited has informed the Exchange about Acquisition
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences Limited's board has approved the acquisition of 100% equity share capital of Avensis Exports Private Limited (AEPL) for a cash consideration of Rs. 24.96 lakhs (80,000 shares at Rs. 31.20 per share). AEPL is a real estate company incorporated in 2007, but has reported nil turnover for the last three financial years (FY22-23, FY23-24, FY24-25) with a paid-up capital of just Rs. 8 lakhs. The acquisition is not a related party transaction and is expected to be completed within one month. The company stated the move is aimed at diversifying into the real estate sector, leveraging AEPL's land exposure and real estate collaborations. Separately, the board also approved a change of Registrar and Share Transfer Agent from KFin Technologies to Alankit Assignments Limited to reduce costs and improve service quality.
This is a small, low-cost diversification move by Nectar Lifesciences (a pharma company) into real estate via a relatively dormant target with no current revenue. Shareholders should view this as a strategic diversification signal rather than a material value-accretive deal, given the negligible deal size. The RTA change is a routine administrative update with no direct impact on shareholders.